Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 ,inter alia, to consider and approve Intimation of Board Meeting to ....

APTUS PHARMA LIMITED Date: 05/08/2026 The BSE Ltd Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400001 SECURITY CODE: 544529 SCRIPT SYMBOL: APPL Dear Sir / Madam, Sub: Prior In(cid:415)ma(cid:415)on of Board Mee(cid:415)ng to be held on Saturday, August 8, 2026. Ref: Regula(cid:415)on 29 of the Securi(cid:415)es and Exchange Board of India (Lis(cid:415)ng Obliga(cid:415)ons and Disclosure Requirements) Regula(cid:415)ons, 2015 (SEBI Lis(cid:415)ng Regula(cid:415)ons) and in(cid:415)ma(cid:415)on regarding closure of trading window. Pursuant to Regula(cid:415)on 29(1)(d) of the Securi(cid:415)es and Exchange Board of India (Lis(cid:415)ng Obliga(cid:415)ons and Disclosure Requirements) Regula(cid:415)ons, 2015, as amended ("SEBI LODR Regula(cid:415)ons"), we hereby give prior in(cid:415)ma(cid:415)on that a Mee(cid:415)ng of the Board of Directors of [Name of the Company] (hereina(cid:332)er referred to as "the Company") is scheduled to be held on Saturday, August 8, 2026 at 4:00 p.m. at the Head office of the Company situated at RK Trade Tower, Wing A, Office 616 to 619, Near Sheetal Park Circle, 150 Feet Ring Road, Rajkot, Gujarat, India, 360006, inter alia, to consider and deliberate upon the following proposed agenda item: 1. To consider, evaluate and deliberate upon the proposal for raising of funds through (a) issuance of equity shares and / or any other eligible securi(cid:415)es by way of Preferen(cid:415)al Allotment, in accordance with the provisions of the Securi(cid:415)es and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regula(cid:415)ons, 2018, as amended ("SEBI ICDR Regula(cid:415)ons"), the Companies Act, 2013 and rules framed thereunder, and other applicable laws and regula(cid:415)ons, subject to such approvals, permissions and sanc(cid:415)ons of the shareholders of the Company and / or regulatory and statutory authori(cid:415)es as may be required; 2. In(cid:415)ma(cid:415)on of Closure of Trading Window Further to the above, and in terms of the Securi(cid:415)es and Exchange Board of India (Prohibi(cid:415)on of Insider Trading) Regula(cid:415)ons, 2015 ("SEBI PIT Regula(cid:415)ons"), as amended, read with the Company's Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons and their Immediate Rela(cid:415)ves framed thereunder ("Code of Conduct"), the Trading Window for dealing in the securi(cid:415)es of the Company stands closed for all Designated Persons and their Immediate Rela(cid:415)ves with effect from 05th August, 2026 (6:00 p.m.), i.e., from the date and (cid:415)me of this in(cid:415)ma(cid:415)on, and shall remain closed un(cid:415)l the expiry of 48 (forty-eight) hours a(cid:332)er the outcome of the aforesaid Board Mee(cid:415)ng is disseminated to the Stock Exchange(s) in terms of Regula(cid:415)on 30 of the SEBI LODR Regula(cid:415)ons. Regd. Address: Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logis(cid:415)c Park, Aslali, Daskroi, Ahmedabad, Gujarat – 382427, India Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM APTUS PHARMA LIMITED All Designated Persons of the Company and their Immediate Rela(cid:415)ves are hereby informed and directed not to trade in the securi(cid:415)es of the Company during the aforesaid period of closure of the trading window. Kindly take the above on record. Thanking You, Yours faithfully, For Aptus Pharma Limited Tejash Hathi Managing Director DIN: 03151221 Regd. Address: Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logis(cid:415)c Park, Aslali, Daskroi, Ahmedabad, Gujarat – 382427, India Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM